Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Moxetumomab pasudotox in relapsed/refractory hairy cell leukemia
NCT01829711Phase 3Completed
- Sponsor
- MedImmune
- Start
- Apr 2013
- Primary completion
- May 2017
- Modality
- Antibody Fragments, Immunotoxins, Monoclonal Antibodies
- Countries
- 14
01
Overview
Phase 3, open-label, single-arm trial of moxetumomab pasudotox in hairy cell leukemia (HCL), sponsored by MedImmune. Primary endpoints: Percentage of Participants With Durable Complete Response Assessed by Blinded Independent Central Review and Percentage of Participants With Durable CR by Investigator's Assessment. Started Apr 2013; status: completed.
02
Drugs
moxetumomab pasudotox
03
Conditions
hairy cell leukemia (HCL)
Beyond the preview
Go deeper on NCT01829711.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01829711.